[Immediate results of parlodel treatment of patients with diffuse toxic goiter complicated by endocrine ophthalmopathy]. 1987

K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva

The authors reported the results of parlodel therapy of 18 patients with diffuse toxic goiter complicated by endocrine ophthalmopathy. The patients ranged in age from 24 to 59 with a period of disease from 3 months to 10 years and more. The drug was given for 6 weeks at a dose of 2.5 mg twice a day after meals, a course dose varied from 150 to 225 mg. A radioimmunoassay was used to determine T3, T4 and TTH, the patients underwent a thorough ophthalmological examination. Six weeks after parlodel therapy was initiated, a decrease in the TTH level up to normal values was observed in parallel with the regression of clinical signs of endocrine ophthalmopathy. The use of parlodel did not change considerably the level of the thyroid hormones T3 and T4.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013972 Thyrotropin A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity. Thyroid-Stimulating Hormone,TSH (Thyroid Stimulating Hormone),Thyreotropin,Thyrotrophin,Hormone, Thyroid-Stimulating,Thyroid Stimulating Hormone
D013974 Thyroxine The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. L-Thyroxine,Levothyroxine,T4 Thyroid Hormone,3,5,3',5'-Tetraiodothyronine,Berlthyrox,Dexnon,Eferox,Eltroxin,Eltroxine,Euthyrox,Eutirox,L-3,5,3',5'-Tetraiodothyronine,L-Thyrox,L-Thyroxin Henning,L-Thyroxin beta,L-Thyroxine Roche,Levo-T,Levothroid,Levothyroid,Levothyroxin Deladande,Levothyroxin Delalande,Levothyroxine Sodium,Levoxine,Levoxyl,Lévothyrox,Novothyral,Novothyrox,O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine,O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine,Oroxine,Sodium Levothyroxine,Synthroid,Synthrox,Thevier,Thyrax,Thyroxin,Tiroidine,Tiroxina Leo,Unithroid,L Thyrox,L Thyroxin Henning,L Thyroxin beta,L Thyroxine,L Thyroxine Roche,Levo T,Thyroid Hormone, T4
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
October 1983, Klinicheskaia meditsina,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
November 1989, Klinicheskaia meditsina,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
January 1998, Klinicheskaia meditsina,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
July 1988, Vrachebnoe delo,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
January 2017, Khirurgiia,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
July 1969, Postgraduate medicine,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
January 1986, Problemy endokrinologii,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
July 1975, Pediatriia,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
January 1980, Terapevticheskii arkhiv,
K N Kazeev, and I V Zinkevich, and G I Karaseva, and L N Kostareva
May 1979, Khirurgiia,
Copied contents to your clipboard!